Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.

Disclosed are immune cell-selective small molecule IMPDH inhibitor compounds and methods of their synthesis and use to treat proliferative disorders.

A non-aqueous electrolyte solution for a battery contains a phosphazene compound (A) that contains at least one of a phosphazene compound represented by Formula (1) or a phosphazene compound represented by Formula (2). In Formulae (1) and (2), each of Y.sup.− and Z.sup.− independently represents an anion in which a proton is removed from an inorganic acid or an active hydrogen compound; each of twenty-four Rs independently represents a hydrocarbon group having from 1 to 10 carbon atoms; and, among the twenty-four Rs, two Rs bonded to the same nitrogen atom are optionally bonded to each other.

##STR00001##

Polyolefin compositions comprising i) a polyolefin, ii) one or more phosphorus—containing benzofuranone compounds and iii) one or more hindered amine light stabilizers are provided excellent protection against discoloration and enhanced thermal stability during melt processing as exhibited by improved retention of molecular weight and maintenance of polymer molecular architecture.

Diphosphites having an open, 3-methylated outer unit and use thereof in hydroformylation.

A process of stabilizing a bidentate or tridentate phosphorus-based phosphite ester ligand or mixture thereof in a hydrocyanation reaction milieu comprising water, wherein the ligand or ligand mixture comprises one or more of (i) a bidentate biphosphite ligand of formula (III), (R.sup.12—X.sup.12) (R.sup.13—X.sup.13) P—X.sup.14—Y—X.sup.24—P(X.sup.22—R.sup.22) (X.sup.23—R.sup.23) or (ii) a tridentate triphosphite ligand of formula (IIIA) (R.sup.12—X.sup.12) (R.sup.13—X.sup.13) P—X.sup.14—Y—X.sup.32—P(X.sup.34—R.sup.34)—(X.sup.33—Y.sup.2—R.sup.24—P(X.sup.23—R.sup.23)—(X.sup.22—R.sup.22) where each X is oxygen or a bond and each Y is an optionally substituted C6-C20 arylene group, comprising admixing the bidentate and/or tridentate with a stabilizing amount of one or more monodentate phosphite ligand of formula P(X.sup.1—R.sup.1)(X.sup.2—R.sup.2)(X.sup.3—R.sup.3) where each X is oxygen or a bond, wherein the monodentate ligand has a rate of hydrolysis greater than the rate of hydrolysis of the bidentate or tridentate ligand in the presence of water in a hydrocyanation reaction milieu, and thereby preserve concentrations and proportions of the bidentate and/or tridentate ligand(s) in the ligand blend.

Provided herein are bridged cyclic phosphates and phosphoramidates (bc-ProTides) of nucleosides, which is a compound, its stereoisomers, isotope-enriched analogs, pharmaceutically acceptable salts, hydrates, solvates, or crystalline or polymorphic forms thereof, with the following structure: ##STR00001##
These compounds can be used for the treatment of viral infections and/or neoplastic diseases in mammals. By optimizing combinations of Y.sub.2, Y.sub.3, R.sup.0, and M, the cleavability of these compounds as prodrugs can be attuned for different tissue targeting with various functional combinations. Also disclosed are processes and methods for preparation of these compounds.

A method for synthesizing (R)-(−)-1-((S)-2-diphosphino ferrocene)-ethyl-diphosphine by: 1) adding vinylferrocene, a chiral catalyst, and toluene to a first drying reactor; adding a phosphorus-hydrogen compound to the first drying reactor and allowing reactants in the first drying reactor to react; cooling the first drying reactor; adding water dropwise to the first drying reactor; extracting, drying, and recrystallizing a product to yield (R)-1-ferrocenylethyl-diphosphine; 2) adding the (R)-1-ferrocenylethyl-diphosphine and ether to a second drying reactor; adding a hexane solution including diethylzinc to the second drying reactor and allowing reactants in the second drying reactor to react; adding a phosphorus-chlorine compound dropwise to the second drying reactor, and heating and refluxing the reaction mixture in the second drying reactor; adding water to quench the reaction mixture in the second drying reactor; and extracting, drying, and recrystallizing the reaction mixture.

Disclosed herein are isotactic polyvinyl ethers and improved methods of making same. The method disclosed herein can produce polyvinyl ethers having a higher isotacticity as compared to polyvinyl ethers prepared with conventional methods.

The invention relates to chiral imidodiphosphates and derivatives thereof having the general formula I, ##STR00001## The compounds are suitable as chiral Brønsted acid catalysts, phase-transfer catalysts, chiral anions for organic salts, metal salts or metal complexes for catalysis.